Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TM4SF1-MYC siRNA conjugate
- Development stage
- Preclinical
- Lead developer
- Tavotek Lab
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
TM4SF1-MYC siRNA conjugate is an antibody-RNA conjugate (ARC) being developed by Tavotek Lab for the treatment of various solid tumors. The therapeutic consists of a monoclonal antibody targeting Transmembrane-4-L-six-family member-1 (TM4SF1) conjugated to a small interfering RNA (siRNA) designed to silence the MYC oncogene. TM4SF1 is a tetraspanin protein frequently overexpressed in gastric, lung, pancreatic, and breast cancers, where it facilitates tumor progression, migration, and angiogenesis. By leveraging the high affinity of the anti-TM4SF1 antibody, the conjugate selectively delivers the MYC siRNA into cancer cells. Once internalized, the siRNA mediates the knockdown of MYC protein, a key driver of cell proliferation and survival in many cancers. Preclinical data presented at AACR 2025 demonstrated that the conjugate is stable and effectively inhibits tumor cell growth in MYC-dependent lung, pancreatic, and gastric cancer models. The program is currently undergoing IND-enabling studies.
- Other names
- TM4SF1-siRNA ARCTM-4SF1-siRNA ARCTM 4SF1-siRNA ARCTM4SF1-MYC siRNA ARCTM-4SF1-MYC siRNA ARCTM 4SF1-MYC siRNA ARC
02
Targets
MYC (MYC proto-oncogene protein)TM4SF1 (Transmembrane 4 L6 family member 1)
Beyond the preview
Go deeper on TM4SF1-MYC siRNA conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TM4SF1-MYC siRNA conjugate.